Skip to main content

ProQR Therapeutics N.V.

corporate_fare Company Profile

ProQR Therapeutics N.V.

PRQR·NASDAQ·Life Sciences·CIK 0001612940

ProQR Therapeutics N.V. is a clinical-stage biotechnology company focused on discovering and developing new therapeutic medicines. The company develops an RNA editing platform using its Axiomer RNA editing technology, aimed at treating genetic disorders where current treatments are insufficient. Its primary product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. ProQR also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. The company has a research and collaboration agreement with Eli Lilly and Company to discover, develop, and commercialize potential new medicines for genetic disorders affecting the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

ProQR Therapeutics N.V. (NASDAQ:PRQR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for PRQR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for PRQR spans 6-K, 4, SCHEDULE 13D/A, 424B5.

Recent high-impact activity:

  • ProQR Posts Q3 2026 Loss of €12.4M, Cash of €103M Funds Runway Into Mid-2028
  • ProQR Posts €12.4M Q3 Loss, Cash of €103M Funds Runway Into Mid-2028
  • ProQR Doses First Patient in Phase 1 Study for Next-Gen Liver Disease Drug AX-0811
  • ProQR Q2 Revenue Doubles to €8.76M, Beats Consensus by 91%
  • ProQR Reports Q2 Results, Announces First Clinical Validation of Axiomer™ RNA Editing Platform

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
€15.91M EUR
Net Income
-€42.18M EUR
Diluted EPS
-€0.40 EUR
Op. Cash Flow
-€52.79M EUR
Free Cash Flow
-€53.81M EUR
Operating Income
-€43.45M EUR
Cash & Equivalents
€92.41M EUR
Debt / Equity
0.00×
Net Margin
-265.2%
Source: 20-F · filed 2026-03-12 · accession 0001104659-26-026713

Short Interest & Short Volume

2.93 days to cover

FINRA reported short interest of 2,888,655 shares in PRQR as of the October 30, 2026 settlement, a 0.7% decrease from the prior period — about 2.9 days to cover at its recent average daily volume. On November 19, 2026, 58.5% of PRQR volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,888,655 shares as of October 30, 2026
Change vs prior period▼ 0.7%
Days to cover2.93 at avg daily volume of 987,535
Daily short volume (FINRA facilities)58.5% of 454,950 shares on November 19, 2026
5-day average short volume63.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for PRQR, detected from its recent SEC filings · based on capital-structure filings through 2026-06-26.

1 recent capital raise1 shelf registration

Capital Raise Finalized · Significant Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

PRQR files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with P →
$1.04 -0.95% today
52-week range · as of 2026-11-12 $1.04 – $2.48
Market cap
$148.18M
Volume
806.9K (0.9× avg)
3-mo avg 853.1K
Live data · 2026-11-20 14:19 UTC · Pre-market

show_chartPrice Chart

Loading chart...

feed PRQR - Latest Insights

PRQR
Nov 12, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.26
Real-time Price: $1.04 info
Change: -$0.220 (-17%) info
Market Cap: $148.178M info
PRQR
Nov 12, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.26
Real-time Price: $1.04 info
Change: -$0.220 (-17%) info
Market Cap: $148.178M info
PRQR
Sep 09, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.05
Real-time Price: $1.04 info
Change: -$1.01 (-49%) info
Market Cap: $148.178M info
PRQR
Aug 13, 2026, 7:11 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.91
Real-time Price: $1.04 info
Change: -$0.870 (-46%) info
Market Cap: $148.178M info
PRQR
Aug 13, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.85
Real-time Price: $1.04 info
Change: -$0.8108 (-44%) info
Market Cap: $148.178M info
PRQR
Aug 13, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.91
Real-time Price: $1.04 info
Change: -$0.870 (-46%) info
Market Cap: $148.178M info
PRQR
Aug 03, 2026, 4:01 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $1.77
Real-time Price: $1.04 info
Change: -$0.730 (-41%) info
Market Cap: $148.178M info
PRQR
Jul 29, 2026, 4:03 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $1.73
Real-time Price: $1.04 info
Change: -$0.690 (-40%) info
Market Cap: $148.178M info
PRQR
Jul 13, 2026, 8:00 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $1.79
Real-time Price: $1.04 info
Change: -$0.750 (-42%) info
Market Cap: $148.178M info
PRQR
Jul 08, 2026, 2:55 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $1.62
Real-time Price: $1.04 info
Change: -$0.575 (-36%) info
Market Cap: $148.178M info
PRQR
Jun 30, 2026, 5:23 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $1.92
Real-time Price: $1.04 info
Change: -$0.880 (-46%) info
Market Cap: $148.178M info
PRQR
Jun 26, 2026, 3:13 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.59
Real-time Price: $1.04 info
Change: -$0.5489 (-35%) info
Market Cap: $148.178M info
PRQR
Jun 25, 2026, 8:15 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $1.50
Real-time Price: $1.04 info
Change: -$0.460 (-31%) info
Market Cap: $148.178M info
PRQR
Jun 25, 2026, 8:12 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.50
Real-time Price: $1.04 info
Change: -$0.460 (-31%) info
Market Cap: $148.178M info
PRQR
Jun 25, 2026, 6:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.91
Real-time Price: $1.04 info
Change: -$0.870 (-46%) info
Market Cap: $148.178M info
PRQR
Jun 25, 2026, 6:25 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.01
Real-time Price: $1.04 info
Change: -$0.970 (-48%) info
Market Cap: $148.178M info
PRQR
Jun 03, 2026, 5:24 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $1.47
Real-time Price: $1.04 info
Change: -$0.430 (-29%) info
Market Cap: $148.178M info
PRQR
Jun 02, 2026, 4:01 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.47
Real-time Price: $1.04 info
Change: -$0.430 (-29%) info
Market Cap: $148.178M info
PRQR
May 12, 2026, 7:09 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $1.59
Real-time Price: $1.04 info
Change: -$0.550 (-35%) info
Market Cap: $148.178M info
PRQR
May 12, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.59
Real-time Price: $1.04 info
Change: -$0.550 (-35%) info
Market Cap: $148.178M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets